Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

RLMD vs VIVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RLMD Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–0 Matrix Metrics)

RLMD Overall Winner 6-Pillar Tally: RLMD 3 – 2 VIVS (1 Tie) Matrix Metrics: RLMD 6 – 0 VIVS

As of Nov 19, 2026, Relmada Therapeutics, Inc. (RLMD) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RLMD carries a Unified Composite Score of 45.5/100 (HOLD) at $3.11 (N/M Forward P/E, 0.0% operating margin), whereas VIVS carries 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin).

  • Technical & Structure Timing Caution: RLMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.3); meanwhile VIVS is in a Breakdown options structure phase (RSI 75.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RLMD vs VIVS
RLMD NASDAQ Head-to-Head Winner
Relmada Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.11
+8.93% 1D
Market Cap $318.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.56β · 109% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 32.0 Fund 54.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.3%), weak momentum, RSI 40
RSI-14: 40.3 · SMA20: $3.69 · SMA50: $3.68
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.83β · 480% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.1 · SMA20: $0.15 · SMA50: $0.18

6-Pillar Scorecard Institutional Category Breakdown (RLMD 3 – 2 VIVS)

Columns: Metric · RLMD · VIVS
1. Valuation Multiples VIVS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 9.6x
2. Growth & Scale RLMD
Revenue Growth (YoY) +0.0% -51.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $112,000
Market Cap $318.5M $2.4M
3. Profitability & Quality RLMD
Gross Margin N/A N/A
Operating Margin 0.0% -10117.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -64.7% -343.1%
4. Balance Sheet & Cash Flow VIVS
Cash Generation (TTM) -$46M -$11M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.82 Book/Sh · -64.7% ROE $1.4M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RLMD
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 93.2% (36th %ile) N/A (N/A)
Put/Call OI Skew 0.08x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RLMD (6) vs VIVS (0)
Institutional Metric RLMD VIVS Criterion Row Edge
Market Capitalization
Scale
$318.5M $2.4M Larger Scale RLMD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -51.4% Higher Growth RLMD
Operating Margin (TTM)
Profitability
0.0% -10117.0% Higher Margin RLMD
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-64.7% -343.1% Higher ROE RLMD
52-Week Range Position
Momentum
5% ($3–$8) 5% ($0–$3) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.56β · 109% Vol 0.83β · 480% Vol Lower Realized Risk RLMD
Unified Institutional Score
Composite Signal
45.5 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite RLMD
Trailing 12M Revenue (USD)
Operating Scale
N/A $112,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 9.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$46M ($1.82 Book/Sh · -64.7% ROE) -$11M EBITDA ($1.4M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIVS +67.81 pp
RLMD: -3.12% · VIVS: +64.69%
3M Horizon VIVS +34.75 pp
RLMD: -32.83% · VIVS: +1.92%
6M Horizon RLMD +21.38 pp
RLMD: -56.87% · VIVS: -78.25%
1Y Horizon RLMD +59.82 pp
RLMD: -27.17% · VIVS: -86.99%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RLMD Revenue VIVS Revenue RLMD Op. Margin VIVS Op. Margin Margin Leader
FY2018 N/A $0M N/A -766.3% VIVS
FY2019 N/A $0M N/A -882.4% VIVS
FY2020 N/A $0M N/A -977.9% VIVS
FY2022 N/A $0M N/A -765.3% VIVS
FY2023 N/A $0M N/A -4792.2% VIVS
FY2024 N/A $0M N/A -13840.4% VIVS
FY2025 N/A $0M N/A -8761.1% VIVS
FY2026 N/A $0M N/A -8768.7% VIVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RLMD BREAKDOWN
137d in phase · OBV DISTRIBUTION
Current IV 93.2%
IV Percentile 36th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact RLMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VIVS BREAKDOWN
73d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RLMD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $318.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VIVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and -10117.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RLMD vs VIVS Key Questions & Quantitative Answers

As of Nov 19, 2026, Relmada Therapeutics, Inc. (RLMD) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RLMD carries a Unified Composite Score of 45.5/100 (HOLD) at $3.11 (N/M Forward P/E, 0.0% operating margin), whereas VIVS carries 36.8/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin). Technical & Structure Timing Caution: RLMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.3); meanwhile VIVS is in a Breakdown options structure phase (RSI 75.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RLMD leads the Growth & Scale pillar: RLMD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VIVS at -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), RLMD cumulative revenue shifted N/A while VIVS shifted N/A. In operating R&D and SG&A reinvestment, RLMD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VIVS.

VIVS screens cheaper on headline valuation multiples. RLMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RLMD (-64.7% ROE) versus VIVS (-343.1% ROE) capital efficiency.

In options market volatility and institutional positioning, RLMD carries 93.2% implied volatility (36th %ile, Balanced (25th–60th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 109% Vol realized risk). By comparison, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.